Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 401–500 of 1,004
Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
de Nijs, R. N. J. (2008) · PubMed · Cited by 87
Øyen, J., Gjesdal, C. G., Brudvik, C. E., HOVE, L. M., Apalset, E. M., Gulseth, H. C., & Haugeberg, G. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1068-x · Cited by 77
“Pharmacological antiresorptive therapy has been shown to reduce the total fracture risk in postmenopausal women [8–10] and vertebral fractures in middle-aged and elderly men with primary osteoporosis [47].”
BackgroundAmir, E., Simmons, C. E., Freedman, O. C., Dranitsaris, G., Cole, D. E. C., Vieth, R., Ooi, W. S., & Clemons, M. J. (2009) · Cancer · doi:10.1002/cncr.24749 · Cited by 78
“6 (median, 33; range, 10204), and these were consistent with the extreme upper range of the first tertile of values derived for urinary Ntelopeptide in previous studies.(24,25) Administration of 10,000 IU per day of vitamin D3 did not have a significant effect on the urinary bone resorption marker urinary N-telopeptid…”
ResultAn overview on the treatment of postmenopausal osteoporosis
Maeda, S. S., & Lazaretti‐Castro, M. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003039 · Cited by 94
“An increased risk of atrial fibrillation was reported in the HORIZON trial (43), but other observational studies have failed in detecting an increased risk with any of the bisphosphonates (47).”
BackgroundEbert, R., Zeck, S., Krug, R., Meißner-Weigl, J., Schneider, D., Seefried, L., Eulert, J., & Jakob, F. J. (2009) · Bone · doi:10.1016/j.bone.2009.01.009 · Cited by 75
“Additionally, antiangiogenic properties of accumulated BP in the bone could also contribute to the pathogenesis of osteonecrosis of the jaw (ONJ), which is a multifaceted complication in patients on long-term ABP treatment, suffering from malignant diseases and often Bone 44 (2009) 858–864 ⁎ Corresponding author.”
BackgroundInfluentialUnmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
Ferrari, S., Reginster, J., Brandi, M. L., Kanis, J. А., Devogelaer, J., Kaufman, J., Féron, J.-M., Kurth, A., & Rizzoli, R. (2016) · Archives of Osteoporosis · doi:10.1007/s11657-016-0292-1 · Cited by 81
“For example, for zoledronic acid, after the first hip fracture, the 30% reduction in the second hip fracture was evident after 16 months of treatment [76, 78, 100, 101].”
BackgroundRaina, D. B., Matuszewski, L.-M., Vater, C., Bolte, J., Isaksson, H., Lidgren, L., Tägil, M., & Zwingenberger, S. (2020) · Science Advances · doi:10.1126/sciadv.abc1779 · Cited by 74
Eastell, R., Nagase, S., Small, M., Boonen, S., Spector, T. D., Ohyama, M., Kuwayama, T., & Deacon, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2047 · Cited by 75
Self-citationRecomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 104
Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling
Sun, X., Zhang, B., Pan, X., Huang, H., Xie, Z., Ma, Y., Hu, B., Wang, J., Chen, Z., & Shi, P. (2019) · The FASEB Journal · doi:10.1096/fj.201900887rr · Cited by 77
Bisphosphonate adverse effects, lessons from large databases
Abrahamsen, B. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833ad677 · Cited by 73
Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial
Grey, A. B., Bolland, M. J., Wattie, D. J., Horne, A. M., Gamble, G. D., & Reid, I. R. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.103 · Cited by 73
“Zoledronate is a potent bisphosphonate that, by virtue of its long skeletal half-life, provides protection against fractures when administered annually by intravenous infusion.((1,2)) It also decreases mortality by 28% after hip fracture.”
BackgroundResultSelf-citationMoorthy, R. S., London, N. J. S., Garg, S. J., & Cunningham, E. T. (2013) · Current Opinion in Ophthalmology · doi:10.1097/01.icu.0000434534.32063.5c · Cited by 77
Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions
Curtis, J. R., & Safford, M. M. (2012) · Drugs & Aging · doi:10.2165/11599620-000000000-00000 · Cited by 78
“Most drug therapies for osteoporosis show significant decreases in vertebral fracture rates as early as 6 months to 1 year after initiation of treatment,([42,95,96]) suggesting that for many patients, the time to reach effective treatment is much shorter than the expected life span.”
InfluentialAssessing response to osteoporosis therapy
Lewiecki, E. M., & Watts, N. B. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0661-8 · Cited by 74
Cameron, D., Douglas, S., Brown, J. E., & Anderson, R. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0899-7 · Cited by 72
“However, it is not certain that bisphosphonates will prevent fractures in these relatively young women, although data from post-menopausal women without breast cancer confirms a protective effect [29].”
BackgroundRelation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation
Bunch, T. J., Anderson, J. L., May, H. T., Muhlestein, J. B., Horne, B. D., Crandall, B. G., Weiss, J. P., LAPPE, D. L., Osborn, J. S., & Day, J. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.037 · Cited by 80
Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives
Brufsky, A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0152 · Cited by 78
Berenson, J. R., Yellin, O., Boccia, R. V., Flam, M. S., Wong, S., Batuman, O., Moezi, M. M., Woytowitz, D., Duvivier, H. L., Nassir, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0666 · Cited by 72
Bauer, D. C., Black, D. M., Bouxsein, M. L., Lui, L.-Y., Cauley, J. A., de Papp, A. E., Grauer, A., Khosla, S., McCulloch, C. E., Eastell, R., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3355 · Cited by 71
“Since 2002, additional large trials with other BPs (zoledronic acid,((12)) ibandronate((13))) and SERMS (bazedoxifene,((14)) lasofoxifene,((15)) and arzoxifene((16))) have been completed.”
BackgroundSelf-citationO’Sullivan, S., Horne, A. M., Wattie, D. J., Porteous, F., Callon, K. E., Gamble, G. D., Ebeling, P. R., Browett, P., & Grey, A. B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2324 · Cited by 74
OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice
de Molon, R. S., Shimamoto, H., Bezouglaia, O., Pirih, F. Q. M., Dry, S., Kostenuik, P. J., Boyce, R. W., Dwyer, D., Aghaloo, T. L., & Tetradis, S. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2490 · Cited by 82
“The HORIZON-Pivotal Fracture Trial (PFT) reported that annual ZA infusions are efficacious in decreasing bone turnover and reducing fracture risk in postmenopausal women with osteoporosis.((58)) Interestingly, in the HORIZON extension, discontinua-”
BackgroundBrozek, W., Reichardt, B., Zwerina, J., Dimai, H. P., Klaushofer, K., & Zwettler, E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3415-4 · Cited by 72
Compression fractures detection on CT
Bar, A., Wolf, L., Amitai, O. B., Toledano, E., & Elnekave, E. (2017) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2249635 · Cited by 72
“Prophylactic treatment of at-risk osteoporotic individuals has been shown to reduce the rate of future hip fracture by 40-70%[6,7,8].”
BackgroundTsai, J. N., Lee, H., David, N. L., Eastell, R., & Leder, B. Z. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30255-4 · Cited by 79
Self-citationMiller, P. D., Pannacciulli, N., Malouf, J., Singer, A. J., Czerwinski, E. J., Bone, H. G., Wang, C., Huang, S., Chines, A. A., Lems, W. F., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05233-x · Cited by 73
Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis
Lippuner, K., Popp, A. W., Schwab, P., Gitlin, M. D., Schaufler, T., Senn, C., & Perrelet, R. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1487-8 · Cited by 75
“This age group is also the typical category of the population in which osteoporosis is diagnosed and treated with a bone active substance proven to reduce fracture risk at the hip, generally a bisphosphonate [34, 35].”
BackgroundŠestak, I., Singh, S., Cuzick, J. M., Blake, G. M., Patel, R., Gossiel, F., Coleman, R. E., Dowsett, M., Forbes, J., Howell, A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71035-6 · Cited by 71
Self-citationEastell, R., Vittinghoff, E., Lui, L., McCulloch, C. E., Pavo, I. J., Chines, A. A., Khosla, S., Cauley, J. A., Mitlak, B., Bauer, D. C., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4433 · Cited by 79
“These included trials of tiludronate,(32) nasal calcitonin,(33) parathyroid hormone 1-84 (PTH 1-84),(30) etidronate,(34) clodronate,(35) zoledronate,(23) abaloparatide,(28) sodium fluoride,(29) romosozumab compared to alendronate,(36) and romosozumab compared to placebo.”
BackgroundSelf-citationRepurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)
Oo, W. M., & Hunter, D. J. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221090297 · Cited by 81
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age
Bolland, M. J., Nisa, Z., Mellar, A., Gasteiger, C., Pinel, V., Mihov, B., Bastin, S., Grey, A. B., Reid, I. R., Gamble, G. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2407031 · Cited by 82
Self-citationTreatment of Osteoporosis and Osteoarthritis in the Oldest Old
Fuggle, N. R., Laslop, A., Rizzoli, R., Al‐Daghri, N. M., Alokail, M. S., Bałkowiec-Iskra, E., Beaudart, C., Bruyère, O., Bemden, A. B., Burlet, N., et al. (2025) · Drugs · doi:10.1007/s40265-024-02138-w · Cited by 91
Osteoporosis and gastrointestinal disease.
Katz, S., & Weinerman, S. A. (2010) · PubMed Central · Cited by 94
RETRACTED: Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women
Jamal, S. A., Hamilton, C. J., Eastell, R., & Cummings, S. R. (2011) · JAMA · doi:10.1001/jama.2011.176 · Cited by 72
Self-citationRetractedKristensen, B., Ejlertsen, B., Mouridsen, H. T., Jensen, M., ANDERSEN, J. E., Jensen, B. B., Cold, S., Edlund, P., Ewertz, M., Kamby, C., et al. (2008) · Acta Oncologica · doi:10.1080/02841860801964988 · Cited by 70
“Interestingly a recent randomised trial has shown that once-yearly infusion of the bisphosphonate zoledronic acid reduces the occurrence of vertebral, hip, and nonvertebral fractures in postmenopausal women [15].”
BackgroundDiretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós‐menopausa
Radominski, S., Bernardo, W. M., de Paula, A. P., Albergaria, B., Moreira, C., Fernandes, C. E., Castro, C. H. D. M., Zerbini, C. A. F., Domiciano, D. S., de Mendonça, L. M. C., et al. (2017) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2017.06.001 · Cited by 193
Watts, N. B., Aggers, D., McCarthy, E. F., Savage, T., Martinez, S., Patterson, R., Carrithers, E., & Miller, P. D. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3081 · Cited by 69
Incorporating adherence into health economic modelling of osteoporosis
Ström, O., Borgström, F., Kanis, J. А., & Jönsson, B. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0644-9 · Cited by 68
“For example, the marked 77% reduction in clinical vertebral fractures with zoledronic acid [ 47 ] may be partially due to better drug compliance.”
BackgroundDiagnosis and management of osteoporosis in the older senior
Vondracek, S. F., & Linnebur, S. A. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4965 · Cited by 87
“001) in HORIZONPFT.(93) There was no difference between groups in serum creatinine or CrCl at the end of the study.”
InfluentialZoledronic acid infusion for lumbar interbody fusion in osteoporosis
Tu, C.-W., Huang, K.-F., Hsu, H.-T., Li, H.-Y., Yang, S. S., & Chen, Y. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.05.034 · Cited by 68
Lee, S., Glendenning, P., & Inderjeeth, C. A. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1335-x · Cited by 73
The Incidence of Acute Anterior Uveitis after Intravenous Zoledronate
Patel, D. V., Horne, A. M., House, M. E., Reid, I. R., & McGhee, C. N. J. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.028 · Cited by 69
Self-citationManagement of Postmenopausal Osteoporosis
Andreopoulou, P., & Bockman, R. S. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-070313-022841 · Cited by 69
Vertebral fracture in postmenopausal Chinese women: a population-based study
Cui, L., Chen, L., Xia, W., Jiang, Y., Cui, L., Huang, W., Wang, W., Wang, X., Pei, Y., Zheng, X. S., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4085-1 · Cited by 76
Self-citationPregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study
Sokal, A., Éléfant, É., Leturcq, T., Beghin, D., Mariette, X., & Séror, R. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4672-9 · Cited by 69
Osteonecrosis of the jaws and bisphosphonates
Pendrys, D. G., & Silverman, S. L. (2008) · Current Osteoporosis Reports · doi:10.1007/s11914-008-0006-8 · Cited by 69
“The HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial) evaluated the safety and efficacy of ZOL, 5 mg, in 7736 women with PMO [ 18 ].”
Anderson, P. M., Kopp, L. M., Anderson, N. R., Cornelius, K., Herzog, C. E., Hughes, D. P. M., & Huh, W. W. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1703 · Cited by 68
“As bisphosphonate use has risen in adults with neoplastic bone disease, osteonecrosis of the jaw (ONJ), atrial fibrillation and renal insufficiency have been identified as potential adverse effects [53,54] .”
BackgroundInfluentialChen, H., Hsu, B. W., Yin, Y.-K., Lin, F., Yang, T.-H., Yang, R., Lee, C., & Tseng, V. S. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245992 · Cited by 82
Reid, I. R., Green, J. R., Lyles, K. W., Reid, D. M., Trechsel, U., Hosking, D. J., Black, D. M., Cummings, S. R., Russell, R. G. G., & Eriksen, E. F. (2020) · Bone · doi:10.1016/j.bone.2020.115390 · Cited by 72
Self-citationIs bone quality associated with collagen age?
Leeming, D. J., Henriksen, K., Byrjalsen, I., Qvist, P., Madsen, S. H., Garnero, P., & Karsdal, M. A. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0904-3 · Cited by 75
“Nevertheless, the reduction in fracture risk is similar among all these treatments [76–80], and SERM, HRT, and calcitonin demonstrate antifracture efficacy approaching that obtained with the more potent antiresorptives [81].”
BackgroundOdanacatib: a review of its potential in the management of osteoporosis in postmenopausal women
Chapurlat, R. D. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15580903 · Cited by 73
CAREY, J. J., & Delaney, M. F. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9064-4 · Cited by 86
Risk Factors for Subtrochanteric and Diaphyseal Fractures: The Study of Osteoporotic Fractures
Napoli, N., Schwartz, A. V., Palermo, L., Jin, J., Wustrack, R. L., Cauley, J. A., Ensrud, K. E., Kelly, M. P., & Black, D. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1896 · Cited by 76
Self-citationChoi, N., Solomon, D. H., Tsacogianis, T., Landon, J. E., Song, H. J., & Kim, S. C. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3019 · Cited by 73
“In a large randomized placebo-controlled trial, zoledronic acid resulted in significantly lower rates of vertebral fractures, hip fractures, and nonvertebral fractures.((16)) Zoledronic acid may cause acute flu-like symptoms for up to 3 days after the first infusion((17)) and has been associated with the possibility o…”
BackgroundReal-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women
Yusuf, A., Cummings, S. R., Watts, N. B., Feudjo, M., Sprafka, J. M., Zhou, J., Guo, H., Balasubramanian, A., & Cooper, C. C. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0439-3 · Cited by 71
Self-citationOnce‐Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture
Boonen, S., ORWOLL, E. S., Magaziner, J. S., Colon-Emeric, C. S., Adachi, J. D., Bucci-Rechtweg, C. M., Haentjens, P., Kaufman, J., Rizzoli, R., Vanderschueren, D., et al. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03666.x · Cited by 69
“In all, 4.5% of men were evaluated or treated, compared with 48.8% of women.15 Zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, has been approved for the treatment and prevention of postmenopausal osteoporosis, with documented antifracture efficacy against vertebral, nonvertebral, and hip fractures in the…”
BackgroundResultInfluentialSelf-citationGrosso, A., Douglas, I., Hingorani, A. D., MacAllister, R. J., & Smeeth, L. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004720 · Cited by 68
“[2] Alterations in serum calcium levels could be related to AF, but the administration of zoledronic acid had little or no effect on serum calcium levels measured 9 to 11 days after infusion.[2] One major limitation of research using routinely collected clinical data is the robustness of the recording information, alt…”
InfluentialWomen in Orthopaedics—Way Behind the Number Curve
Lewis, V. O., Scherl, S. A., & O’Connor, M. I. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.01408 · Cited by 67
Welton, J. L., Morgan, M. P. G., Martí, S., Stone, M. D., Moser, B., Sewell, A. K., Turton, J., & Eberl, M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1797 · Cited by 67
Inderjeeth, C. A., Foo, A. C. H., Lai, M. M. Y., & Glendenning, P. (2008) · Bone · doi:10.1016/j.bone.2008.12.003 · Cited by 71
“[49] randomised 3889 postmenopausal, osteoporotic women,mean age 73 ±5 (range 65–89) years, to either an annual infusion of zoledronic acid 5 mg or placebo at baseline with 12, 24 and 36 months of follow up.”
MethodIs Zoledronate Toxic to Human Periodontal Fibroblasts?
Agis, H., Blei, J., Watzek, G., & Gruber, R. (2009) · Journal of Dental Research · doi:10.1177/0022034509354298 · Cited by 70
High risk of osteoporosis in male patients with eating disorders
Mehler, P. S., Sabel, A. L., Watson, T., & Andersen, A. E. (2008) · International Journal of Eating Disorders · doi:10.1002/eat.20554 · Cited by 67
Fracture risk following intermission of osteoporosis therapy
On behalf of the IOF Epidemiology/Quality of Life Working Group, Dennison, E. M., Cooper, C. C., Kanis, J. A., Bruyère, O., Silverman, S. S., McCloskey, E. V., Abrahamsen, B., Prieto‐Alhambra, D., & Ferrari, S. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05002-w · Cited by 68
Postmenopausal Osteoporosis: A Literature Review
Bhatnagar, A., & Kekatpure, A. L. (2022) · Cureus · doi:10.7759/cureus.29367 · Cited by 105
“Some bisphosphonates available for treatment in India are listed in Table 2 [96-101].”
BackgroundYang, J.-G., Sun, B., Wang, Z., Li, X., Gao, J.-H., Qian, J., Li, J., Wei, W.-J., Zhang, P., & Wang, W. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06263-4 · Cited by 76
Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases
Ganda, K., & Seibel, M. J. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2585-1 · Cited by 67
“This spike in PTH levels has been reported in patients with osteoporosis treated with IV bisphosphonates or sc denosumab [23, 24].”
BackgroundIntravenous Bisphosphonate Therapy and Bisphosphonate-Related Osteonecrosis of the Jaws
Dodson, T. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.12.004 · Cited by 66
Bouxsein, M., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080301 · Cited by 73
Self-citationLooking Beyond Recurrence: Comorbidities in Cancer Survivors
Edgington, A. A., & Morgan, M. A. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.e3-e12 · Cited by 68
“Diabetes is a metabolic disease characterized by hyperglycemia attributable to defects in insulin resistance or action,”
Bone health and osteoporosis in postmenopausal women
de Villiers, T. J. (2008) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2008.10.009 · Cited by 86
Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis
Zahrowski, J. J. (2009) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2008.08.017 · Cited by 85
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
Fuggle, N. R., Cooper, C. C., Harvey, N. C., Al‐Daghri, N. M., Brandi, M. L., Bruyère, O., Cano, A., Dennison, E. M., Díez‐Pérez, A., Kaufman, J., et al. (2020) · Drugs · doi:10.1007/s40265-020-01364-2 · Cited by 79
Diacinti, D., & Guglielmi, G. (2010) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2010.02.018 · Cited by 79
Cosman, F. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0596 · Cited by 71
Self-citationPrevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies
Bonura, F. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2021 · Cited by 77
Diagnosis and Treatment of Osteoporosis in Chronic Renal Disease
Miller, P. D. (2009) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2009.01.007 · Cited by 63
der Kallen, J. V., Giles, M., Cooper, K., Gill, K., Parker, V., Tembo, A. C., Major, G. A. C., Ross, L. A., & Carter, J. (2013) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12101 · Cited by 65
Current approaches to osteoporosis treatment
Lim, S. Y., & Bolster, M. B. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000169 · Cited by 71
González-Macías, J., del Pino‐Montes, J., Olmos, J. M., & Nogués, X. (2015) · Revista Clínica Española · doi:10.1016/j.rce.2015.08.003 · Cited by 82
Polascik, T. J. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s3169 · Cited by 69
Monitoring osteoporosis treatment
Compston, J. E. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.007 · Cited by 65
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
Raterman, H. G., Bultink, I. E. M., & Lems, W. F. (2019) · Drugs · doi:10.1007/s40265-019-01145-6 · Cited by 65
Osteoporosis treatments and adverse events
Solomon, D. H., Rekedal, L., & Cadarette, S. M. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832ca433 · Cited by 65
Teotia, A. K., Gupta, A., Raina, D. B., Lidgren, L., & Kumar, A. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b02145 · Cited by 63
Ekman, E. F. (2010) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-201005000-00004 · Cited by 70
“In a study of 7,765 postmenopausal women, zoledronic acid administration decreased vertebral fracture by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years versus placebo.(32) In this same study, zoledronic acid increased total hip BMD by 6.”
BackgroundOnce-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
Lambrinoudaki, I. V. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2046 · Cited by 62
“Additionally, 0.2% of patients treated with zoledronic acid developed iritis, uveitis, episcleritis (Black et al 2007).”
InfluentialActualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.013 · Cited by 90
A reappraisal of generic bisphosphonates in osteoporosis
Kanis, J. А., Reginster, J., Kaufman, J., Ringe, J. D., Adachi, J. D., Hiligsmann, M., Rizzoli, R., & Cooper, C. C. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1796-6 · Cited by 68
“Of the available options, alendronate, risedronate, zoledronic acid, denosumab and strontium ranelate reduce vertebral, non-vertebral and hip fractures [7–15] (see Table 1).”
BackgroundRaina, D. B., Larsson, D., Mrkonjic, F., Isaksson, H., Kumar, A., Lidgren, L., & Tägil, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.006 · Cited by 62
“Systemic ZA administration has been the most preferred route but side effects like osteonecrosis of the jaw [19], reduced skeletal remodeling or flu like symptoms [20] have been reported, which have made local delivery of ZA interesting.”
BackgroundSeeman, E., Boonen, S., Borgström, F., Vellas, B. J., Aquino, J., Semler, J., Benhamou, C.-L., Kaufman, J., & Reginster, J. (2009) · Bone · doi:10.1016/j.bone.2009.12.006 · Cited by 75
“The only studies examining antifracture efficacy in this age group report a reduction in vertebral, but not nonvertebral, fractures [5–8].”
BackgroundSelf-citationBisphosphonate-Induced Osteonecrosis of the Jaws, Bone Markers, and a Hypothesized Candidate Gene
Lehrer, S., Montazem, A. H., Ramanathan, L. V., Pessin, M. S., Pfail, J. L., Stock, R. G., & Kogan, R. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.09.015 · Cited by 79
Bisphosphonate-Associated Orbital Inflammation—A Case Report And Review
Peterson, J. D., & Bedrossian, E. H. (2012) · Orbit · doi:10.3109/01676830.2011.648818 · Cited by 62
Red blood cell transfusion in critically ill children: A narrative review*
Istaphanous, G. K., Wheeler, D. S., Lisco, S. J., & Shander, A. (2010) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181e30d09 · Cited by 62
Mathavan, N., Bosemark, P., Isaksson, H., & Tägil, M. (2013) · Bone · doi:10.1016/j.bone.2013.06.030 · Cited by 66
“Bisphosphonate therapy is established in improving the clinical outcomes of osteoporosis and several metabolic bone disorders characterized by excessive bone resorption [26,27,36].”
BackgroundPharmacological management of osteogenesis
Nardone, V., D’Asta, F., & Brandi, M. L. (2014) · Clinics · doi:10.6061/clinics/2014(06)12 · Cited by 67
Bisphosphonates for post-menopausal osteoporosis: are they all the same?
Rizzoli, R. (2011) · QJM · doi:10.1093/qjmed/hcq259 · Cited by 67
“7% with once-yearly zoledronic acid.(18) The ability to improve BMD at other sites is more variable.”
BackgroundResultInfluentialMori, H., Tanaka, M., Kayasuga, R., Masuda, T., Ochi, Y., Yamada, H., Kishikawa, K., Ito, M., & Nakamura, T. (2008) · Bone · doi:10.1016/j.bone.2008.07.242 · Cited by 66
Organic–Inorganic Hybrid Metal Phosphonates as Recyclable Heterogeneous Catalysts
Bhanja, P., & Bhaumik, A. (2016) · ChemCatChem · doi:10.1002/cctc.201501303 · Cited by 62
Paschalis, E. P., Gamsjaeger, S., Hassler, N., Fahrleitner‐Pammer, A., Dobnig, H., Stepan, J. J., Pavo, I. J., Eriksen, E. F., & Klaushofer, K. (2016) · Bone · doi:10.1016/j.bone.2016.11.002 · Cited by 69
Self-citationBisphosphonates in the Treatment of Osteoporosis
Diab, D. L., & Watts, N. B. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.007 · Cited by 62
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.